FDA Approval History and Background of Advil Chewable Tablets

The U.S. Food and Drug Administration (FDA) has approved Haleon's (HLE) pediatric fever and pain reliever, Advil Chewable Tablets (active ingredient: Ibuprofen). This drug initially received its first approval on December 18, 1998, through a New Drug Application (NDA 020944), and has since undergone continuous regulatory updates to expand its presence in the pediatric over-the-counter (OTC) market. Advil works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby blocking prostaglandin synthesis, effectively relieving pain and fever in children. This approval is highly significant from a public health perspective, as it provides an additional, safe, and proven dosage form for pediatric patients.

Competitive Landscape in the Pediatric Fever and Pain Reliever Market

The global pediatric fever and pain reliever market is currently dominated by Johnson & Johnson (JNJ)'s Tylenol (active ingredient: Acetaminophen) and Motrin (active ingredient: Ibuprofen). Ibuprofen, unlike acetaminophen, also has anti-inflammatory properties, providing a differentiated clinical benefit in managing fever and pain associated with inflammation. Haleon's Advil Chewable Tablets offer the convenience of a chewable formulation that can be taken without water, allowing it to compete fiercely with rival products for market share. This formulation innovation improves medication adherence and significantly enhances treatment convenience in pediatric clinical settings and at home.

Growth and Economic Value of the Global Pediatric Pharmaceutical Market

The global pediatric pain and fever relief market, including pediatric fever and pain relievers, is estimated at approximately $3.4 billion (approximately 4.5 trillion Korean Won) in 2025 and is projected to grow at a compound annual growth rate of approximately 6.3% to reach $4.61 billion by 2030. The recent surge in pediatric infectious diseases, combined with increased parental interest in children's health, has led to a rapid increase in demand for high-quality fever medications. Haleon aims to solidify its core brand, Advil, in the pediatric segment and secure a stable source of revenue amidst these market dynamics. By combining brand recognition and consumer trust, it is building a solid foundation for expanding its market share.

Challenges in Securing OTC Distribution Channels and Ensuring Regulatory Compliance

Due to the limited scope of insurance reimbursement in the U.S. OTC market, it is crucial to diversify distribution channels to encourage direct purchases by consumers. Haleon faces the business challenge of maximizing product accessibility by expanding partnerships with major retailers and pharmacy chains. Furthermore, as a pediatric product, it is essential to implement thorough risk management measures, including clear labeling and precise age-based dosage guidelines, to prevent misuse. The combination of these marketing and distribution capabilities will be a key indicator in determining the actual market penetration rate and long-term profitability of the new product.